phenylalanine has been researched along with metformin in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.82) | 18.7374 |
| 1990's | 2 (3.64) | 18.2507 |
| 2000's | 45 (81.82) | 29.6817 |
| 2010's | 6 (10.91) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, S; Chaturvedi, A; Heuser, M; Joshi, G; Kumar, R; Patil, S | 1 |
| Abdel-Wahab, MF; el-Kirdassy, ZH; Hafiez, AA; Ismail, AA; Khater, RA; Megahed, YM | 1 |
| Biolo, G; Bruttomesso, D; Fongher, C; Inchiostro, S; Panebianco, G; Tessari, P; Tiengo, A; Vedovato, M | 1 |
| Smits, P; Tack, CJ | 1 |
| Hirschberg, Y; Karara, AH; McLeod, JF; Pietri, AO | 1 |
| Clinkingbeard, C; Foley, J; Gatlin, M; Horton, ES; Mallows, S; Shen, S | 1 |
| Hanif, W; Kumar, S | 1 |
| Yudkin, JS | 1 |
| Nelson, G | 1 |
| Andrews, J | 1 |
| Ahmann, AJ; Riddle, MC | 1 |
| Ball, M; Guitard, C; Marre, M; Usadel, KH; Van Gaal, L; Whatmough, I | 1 |
| Shiba, T | 1 |
| Iguchi, A; Satake, S | 1 |
| Caro, J; Salas, M; Ward, A | 1 |
| Hale, PM; Hollander, P; Khutoryansky, N; Klaff, L; McGill, J; Raskin, P; South, SA | 1 |
| Del Prato, S; Emmons, RP; Guitard, C; Heine, RJ; Keilson, L; Shen, SG | 1 |
| Odawara, M | 1 |
| Lehwalder, D; Schandry, R; Schatz, H; Schoppel, K | 1 |
| Baron, MA | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Baron, MA; Foley, JE; Horton, ES; Shen, SG | 1 |
| Atkin, SL; Robertson, D; Weaver, JU | 1 |
| Gall, MA; Lammert, M; Minshall, ME; Nicklasson, L; Palmer, AJ; Roze, S; Spinas, GA; Valentine, WJ | 1 |
| Ashokkumar, N; Pari, L | 2 |
| Kawamori, R | 1 |
| Ashokkumar, N; Manimekalai, A; Pari, L; Selvaraju, K | 1 |
| Abdel-Salam, OM; Baiuomy, AR; El-Batran, SA; Nofal, SM | 1 |
| Desai, M; Huang, WX; Joshi, Y; Tang, Q; Vivilecchia, RV; Yang, R | 1 |
| Campbell, A | 1 |
| Kumar, NA; Pari, L | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S | 1 |
| Ashokkumar, N; Pari, L; Rao, ChA | 1 |
| Ashwell, SG; Dashora, UK; Home, PD; Sibal, L | 1 |
| Black, C; Donnelly, P; McIntyre, L; Royle, PL; Shepherd, JP; Thomas, S | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P | 1 |
| Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Salvadeo, S | 2 |
| Baron, MA; Israel, MK; Istvan, E | 1 |
| Juurinen, L; Kauppinen-Mäkelin, R; Kock, T; Kotronen, A; Lanki, H; Leppävuori, E; Nikkilä, K; Saltevo, J; Teikari-Myyrä, T; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Davis, SN | 1 |
| Buse, JB; Einhorn, D | 1 |
| Wang, L; Yang, JK | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| DeFronzo, RA; Ferrannini, E | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Gaud, R; Wairkar, S | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
16 review(s) available for phenylalanine and metformin
| Article | Year |
|---|---|
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Nateglinide: a new rapid-acting insulinotropic agent.
Topics: Animals; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Guidelines as Topic; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Microcirculation; Molecular Structure; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
Restoring post-prandial insulin release in type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
Current oral agents for type 2 diabetes. Many options, but which to choose when?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycoside Hydrolases; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Transcription Factors | 2002 |
[Metformin--its regimen and effects].
Topics: Acarbose; Biguanides; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Patient Selection; Phenylalanine; Sulfonylurea Compounds; Treatment Outcome | 2002 |
[Management guideline for elderly diabetic patients].
Topics: Aged; Cyclohexanes; Diabetes Mellitus; Diet, Diabetic; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Practice Guidelines as Topic; Sulfonylurea Compounds | 2002 |
Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
Topics: Aged; Blood Glucose; Body Mass Index; Comorbidity; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Retrospective Studies | 2003 |
[Nateglinide and mitiglinide].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Metformin; Nateglinide; Phenylalanine; Postprandial Period; Stimulation, Chemical | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy; Glucose; Glucose Intolerance; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Glycaemic control in type 2 diabetes.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Patient Education as Topic; Phenylalanine; Sulfonylurea Compounds | 2005 |
Meglitinide analogues for type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic | 2007 |
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Thiazolidinediones; United States; Weight Gain | 2000 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Piperidines; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Topics: Adult; Benzamides; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Middle Aged; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2016 |
17 trial(s) available for phenylalanine and metformin
| Article | Year |
|---|---|
Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.
Topics: Amino Acids; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Food; Glucagon; Humans; Kinetics; Male; Metformin; Middle Aged; Phenylalanine; Placebos; Proteins; Tritium | 1994 |
Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Topics: Adult; Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2000 |
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Eating; Ethnicity; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies; United States | 2000 |
Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Racial Groups; Safety; Triglycerides | 2002 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Topics: Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Safety | 2003 |
Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Product Surveillance, Postmarketing | 2003 |
Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Treatment Outcome; United States | 2004 |
Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Regression Analysis | 2004 |
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2006 |
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2007 |
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Safety; Time Factors | 2007 |
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
Topics: Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Plasminogen Activator Inhibitor 1; Tissue Plasminogen Activator | 2007 |
Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Hemodynamics; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine | 2009 |
Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Young Adult | 2009 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
22 other study(ies) available for phenylalanine and metformin
| Article | Year |
|---|---|
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Topics: Allosteric Regulation; Allosteric Site; Carrier Proteins; Chemistry, Pharmaceutical; Glycolysis; Humans; Membrane Proteins; Protein Kinase Inhibitors; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2022 |
Inhibitory effect of metformin on L-B-phenyl alanine-125 absorption in man.
Topics: Adult; Humans; Intestinal Absorption; Metformin; Phenylalanine | 1976 |
Nateglinide for type 2 diabetes.
Topics: Administration, Oral; Cyclohexanes; Diabetes Mellitus, Type 2; Dizziness; Humans; Metformin; Nateglinide; Phenylalanine | 2001 |
[Type 2 diabetes. Regulating insulin according to need].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones | 2001 |
Post-load hyperglycaemia-an inappropriate therapeutic target.
Topics: Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Patient Selection; Phenylalanine; Postprandial Period; Practice Guidelines as Topic; Predictive Value of Tests | 2002 |
Type 2 diabetes management.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2002 |
[Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
[Islands cells are not activated quickly enough. Risk of obstruction of blood vessels].
Topics: Arteriosclerosis; Blood Glucose; Cyclohexanes; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Nateglinide; Phenylalanine; Postprandial Period; Risk | 2002 |
Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cohort Studies; Costs and Cost Analysis; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
[Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2003 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2003 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexanes; Decision Support Systems, Clinical; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Male; Metformin; Middle Aged; Models, Econometric; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Piperidines; Quality-Adjusted Life Years | 2004 |
Effect of N-benzoyl-D-phenylalanine and metformin on carbohydrate metabolic enzymes in neonatal streptozotocin diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Eating; Female; Gluconeogenesis; Glucosephosphate Dehydrogenase; Glycated Hemoglobin; Glycolysis; Hemoglobins; Hexokinase; Hypoglycemic Agents; Lipids; Liver; Liver Glycogen; Male; Metformin; Phenylalanine; Rats; Rats, Wistar | 2005 |
Effect of N-benzoyl-D-phenylalanine on streptozotocin-induced changes in the lipid and lipoprotein profile in rats.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fatty Acids, Nonesterified; Glucosephosphate Dehydrogenase; Hypoglycemic Agents; Lipid Peroxidation; Lipids; Lipoproteins; Metformin; Phenylalanine; Rats; Rats, Wistar; Triglycerides | 2005 |
Effect of N-benzoyl-d-phenylalanine on lipid profile in liver of neonatal streptozotocin diabetic rats.
Topics: Administration, Oral; Animals; Animals, Newborn; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glutathione; Hypoglycemic Agents; Insulin; Lipid Peroxidation; Lipids; Liver; Male; Metformin; Phenylalanine; Rats; Rats, Wistar; Streptozocin; Thiobarbituric Acid Reactive Substances | 2005 |
Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Cholesterol; Cyclohexanes; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Metformin; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Elimination of metformin-croscarmellose sodium interaction by competition.
Topics: Arginine; Binding, Competitive; Carboxymethylcellulose Sodium; Cyclohexanes; Drug Combinations; Excipients; Hypoglycemic Agents; Metformin; Models, Chemical; Nateglinide; Phenylalanine; Tablets; Technology, Pharmaceutical | 2006 |
Combined n-benzoyl-d-phenylalanine and metformin treatment reverses changes in the fatty acid composition of streptozotocin diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fatty Acids; Fatty Acids, Unsaturated; Hypoglycemic Agents; Insulin; Kidney; Lipid Metabolism; Liver; Metformin; Phenylalanine; Rats; Rats, Wistar | 2006 |
Effect of N-benzoyl-D-phenylalanine and metformin on insulin receptors in neonatal streptozotocin-induced diabetic rats: studies on insulin binding to erythrocytes.
Topics: Animals; Animals, Newborn; Binding, Competitive; Blood Glucose; Diabetes Mellitus, Experimental; Erythrocyte Membrane; Female; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Phenylalanine; Pregnancy; Protein Binding; Rats; Rats, Wistar; Receptor, Insulin; Streptozocin | 2006 |
Panel discussion on achieving glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2001 |
Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Topics: Aged; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Product Surveillance, Postmarketing; Prospective Studies | 2013 |
Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement.
Topics: Chemistry, Pharmaceutical; Cyclohexanes; Drug Combinations; Metformin; Nateglinide; Phenylalanine; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |